{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:01:39Z","timestamp":1789970499570,"version":"4.0.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between carvedilol use and mortality in patients with sepsis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All adult critically ill patients with sepsis were retrospectively identified from the MIMIC-IV database. Patients who received carvedilol between sepsis diagnosis and Intensive Care Unit(ICU) discharge were designated as the intervention group and were matched 1:1 with non-users using propensity score matching. The primary outcomes were 28-day and 365-day all-cause mortality, and the secondary outcome was in-hospital mortality. Kaplan\u2013Meier survival curves and Cox proportional hazards regression models were used to examine the association between carvedilol and outcomes. Subgroup analyses and sensitivity analyses including time-dependent Cox regression were conducted to test robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33,453 patients were included, of whom 1,084 received carvedilol. After propensity score matching, 1,082 pairs were successfully matched. Kaplan\u2013Meier survival curves showed significant differences in survival probabilities between the two groups. After adjusting for confounders using multivariate Cox regression, the hazard ratios (95% confidence intervals) for carvedilol use on 28-day and 365-day all-cause mortality were 0.53 (0.43\u20130.66) and 0.66 (0.57\u20130.76), respectively. Furthermore, carvedilol use was associated with lower in-hospital mortality (OR = 0.49, 95% CI: 0.37\u20130.64; P &amp;lt; 0.001). Subgroup and sensitivity analyses supported the robustness of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Carvedilol use during the period from sepsis diagnosis to ICU discharge was associated with reduced mortality in critically ill patients with sepsis. However, prospective studies are warranted to further guide the use of carvedilol in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1796036","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:59Z","timestamp":1789968959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of carvedilol with mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Hua","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohao","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurotrauma and Neurocritical Care Medicine, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhan","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlian","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Emergency, Zhujiang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1139\/cjpp-2014-0508","article-title":"Low-dose carvedilol protects against acute septic renal injury in rats during the early and late phases","volume":"93","author":"Abdel Kawy","year":"2015","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/01.CCM.0000050459.35390.5B","article-title":"Cytokines down-regulate \u03b11-adrenergic receptor expression during endotoxemia","volume":"31","author":"Bucher","year":"2003","journal-title":"Crit. Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/0300060517746996","article-title":"Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms","volume":"46","author":"Burgdorff","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/HJH.0b013e328012a8c6","article-title":"Antioxidant activity of carvedilol in cardiovascular disease","volume":"25","author":"Dandona","year":"2007","journal-title":"J. Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1489657","DOI":"10.3389\/fphar.2024.1489657","article-title":"\u03b2-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress","volume":"15","author":"Dryga\u0142a","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0014-2999(98)00479-9","article-title":"SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits","volume":"357","author":"Feuerstein","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"A88","DOI":"10.1186\/2197-425X-3-S1-A88","article-title":"90-day mortality of severe sepsis and septic shock is reduced by initiation of oral beta-blocker therapy and increased by discontinuation of a pre-existing beta-blocker treatment","volume":"3","author":"Fuchs","year":"2015","journal-title":"Intensive Care Med. Exp."},{"key":"B11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejphar.2017.08.027","article-title":"Carvedilol abrogates hypoxia-induced oxidative stress and neuroinflammation in microglial BV2 cells","volume":"814","author":"Gao","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/SHK.0000000000000676","article-title":"Association of heart rate with N-terminal pro-B-type natriuretic peptide in septic patients: a prospective observational cohort study","volume":"46","author":"Hayase","year":"2016","journal-title":"Shock"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCOUTCOMES.109.875658","article-title":"Missing data analysis using multiple imputation: getting to the heart of the matter","volume":"3","author":"He","year":"2010","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Pathophysiology of sepsis-induced cardiomyopathy","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41597-022-01899-x","article-title":"MIMIC-IV, a freely accessible electronic health record dataset","volume":"10","author":"Johnson","year":"2023","journal-title":"Sci. Data"},{"key":"B16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3923\/ijp.2023.296.304","article-title":"Exploring beta blockers\u2018 efficacy in sepsis-induced acute lung injury and HMGB1-sRAGE interaction","volume":"19","author":"Karaali","year":"2023","journal-title":"Int. J. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s12072-019-09986-9","article-title":"Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial","volume":"13","author":"Kumar","year":"2019","journal-title":"Hepatol. Int."},{"key":"B18","first-page":"S1490","article-title":"Effects of oral administration of carvedilol on mortality and inflammatory responses to endotoxin-induced shock in rats","volume":"120","author":"Kurita","year":"2009","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e87649","DOI":"10.7759\/cureus.87649","article-title":"Carvedilol vs. metoprolol effectiveness in patients with left ventricular assist devices: a TriNetX analysis","volume":"17","author":"Nwaezeapu","year":"2025","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17642","DOI":"10.1161\/circ.134.suppl_1.17642","article-title":"Carvedilol improves prognosis in sepsis-induced cardiomyopathy through the activation of \u201ctelomere-p53-PGC\u201d signaling","volume":"134","author":"Okada","year":"2016","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/a:1007738421993","article-title":"Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure","volume":"11","author":"Ruffolo","year":"1997","journal-title":"Cardiovasc Drugs Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1448015","DOI":"10.3389\/fphar.2024.1448015","article-title":"Impact of \u03b2-blockers on in-hospital mortality in patients with heart failure: a retrospective propensity-score matched analysis based on MIMIC-IV database","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0325980","DOI":"10.1371\/journal.pone.0325980","article-title":"Association between the early use of beta-blocker and the risk of sepsis-associated acute kidney injury: a retrospective cohort study using the MIMIC-IV database","volume":"20","author":"Wang","year":"2025","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1272871","DOI":"10.3389\/fmed.2023.1272871","article-title":"Association between the \u03b2-blocker use and patients with sepsis: a cohort study","volume":"10","author":"Yang","year":"2023","journal-title":"Front. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1796036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:36:00Z","timestamp":1789968960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1796036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":27,"alternative-id":["10.3389\/fphar.2026.1796036"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1796036","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1796036"}}